Canada markets open in 2 hours 39 minutes

Gritstone bio, Inc. (GRTS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.1200-0.0400 (-1.85%)
At close: 04:00PM EST
2.1200 0.00 (0.00%)
Pre-Market: 06:17AM EST
Full screen
Trade prices are not sourced from all markets
Previous Close2.1600
Open2.1500
Bid0.0000 x 2200
Ask0.0000 x 1300
Day's Range2.1100 - 2.2350
52 Week Range1.1400 - 3.3300
Volume1,099,673
Avg. Volume1,943,893
Market Cap202.125M
Beta (5Y Monthly)0.37
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Gritstone bio Announces Update to Comparative Phase 2b COVID-19 Clinical Trial

    EMERYVILLE, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that it is now preparing to launch the Phase 2b head-to-head trial of its next-generation COVID-19 vaccine in the Fall of 2024 rather than 1Q24. This is to allow use of fully GMP-grade raw materials in the vaccine, which is expected to increase the regulatory utility of the trial. “After recent commun

  • GlobeNewswire

    Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    EMERYVILLE, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that the Compensation Committee of the company’s Board of Directors granted six employees nonqualified stock options to purchase an aggregate of 147,000 shares of its common stock with an exercise price of $2.26, which is equal to the closing price of Gritstone’s common stock on February 6, 2024, th

  • GlobeNewswire

    Gritstone bio to Participate in Upcoming Investor Conference

    EMERYVILLE, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that management will be participating in the following investor conference: B. Riley Securities' 4th Annual Oncology Conference (Fireside Chat)Date and Time: Thursday, January 18, 2024 at 1:30pm ETPresenter: Andrew Allen, M.D., Ph.D., Co-founder, President, and Chief Executive Officer A live webcast o